25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NMRA (Neumora Therapeutics, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze Neumora Therapeutics, Inc. together

I guess you are interested in Neumora Therapeutics, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Neumora Therapeutics, Inc.’s Financial Insights
  • 📈 Technical Analysis (TA) – Neumora Therapeutics, Inc.’s Price Targets

I'm going to help you getting a better view of Neumora Therapeutics, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Neumora Therapeutics, Inc.

I send you an email if I find something interesting about Neumora Therapeutics, Inc..

1. Quick Overview

1.1. Quick analysis of Neumora Therapeutics, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Neumora Therapeutics, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.77
Expected worth in 1 year
$0.65
How sure are you?
11.8%

+ What do you gain per year?

Total Gains per Share
$-1.12
Return On Investment
-109.1%

For what price can you sell your share?

Current Price per Share
$1.03
Expected price per share
$0 - $1.83
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Neumora Therapeutics, Inc. (5 min.)




Live pricePrice per Share (EOD)
$1.03
Intrinsic Value Per Share
$-13.13 - $-15.40
Total Value Per Share
$-11.36 - $-13.63

2.2. Growth of Neumora Therapeutics, Inc. (5 min.)




Is Neumora Therapeutics, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$287m$208.4m$144.9m41.0%

How much money is Neumora Therapeutics, Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$60.9m-$58.9m-$1.9m-3.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Neumora Therapeutics, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Neumora Therapeutics, Inc.?

Welcome investor! Neumora Therapeutics, Inc.'s management wants to use your money to grow the business. In return you get a share of Neumora Therapeutics, Inc..

First you should know what it really means to hold a share of Neumora Therapeutics, Inc.. And how you can make/lose money.

Speculation

The Price per Share of Neumora Therapeutics, Inc. is $1.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neumora Therapeutics, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neumora Therapeutics, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.77. Based on the TTM, the Book Value Change Per Share is $-0.28 per quarter. Based on the YOY, the Book Value Change Per Share is $1.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neumora Therapeutics, Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.36-35.3%-0.38-36.5%-0.36-35.4%-0.32-30.6%-0.32-30.6%
Usd Book Value Change Per Share-0.21-20.2%-0.28-27.3%1.41137.2%0.1010.1%0.1010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.21-20.2%-0.28-27.3%1.41137.2%0.1010.1%0.1010.1%
Usd Price Per Share10.60-11.85-7.79-4.62-4.62-
Price to Earnings Ratio-7.30--7.95--4.28--2.88--2.88-
Price-to-Total Gains Ratio-50.99--43.29--30.55--39.04--39.04-
Price to Book Ratio5.98-5.52-2.59-1.91-1.91-
Price-to-Total Gains Ratio-50.99--43.29--30.55--39.04--39.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.03
Number of shares970
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.280.10
Usd Total Gains Per Share-0.280.10
Gains per Quarter (970 shares)-272.49101.12
Gains per Year (970 shares)-1,089.97404.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1090-11000404394
20-2180-21900809798
30-3270-3280012131202
40-4360-4370016181606
50-5450-5460020222010
60-6540-6550024272414
70-7630-7640028312818
80-8720-8730032363222
90-9810-9820036403626
100-10900-10910040454030

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.09.01.016.7%2.012.03.011.8%2.012.03.011.8%2.012.03.011.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%2.09.01.016.7%2.012.03.011.8%2.012.03.011.8%2.012.03.011.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Neumora Therapeutics, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.208-0.281+35%1.414-115%0.104-299%0.104-299%
Book Value Per Share--1.7722.182-19%1.287+38%-0.096+105%-0.096+105%
Current Ratio--10.50814.177-26%16.633-37%14.753-29%14.753-29%
Debt To Asset Ratio--0.0940.075+26%0.652-86%1.114-92%1.114-92%
Debt To Equity Ratio--0.1040.081+28%0.048+117%0.030+243%0.030+243%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1994647484.8002252208797.280-11%2975818944.640-33%2493412179.733-20%2493412179.733-20%
Eps---0.363-0.376+4%-0.364+0%-0.315-13%-0.315-13%
Ev To Ebitda Ratio---7.945-8.630+9%-10.048+26%-9.103+15%-9.103+15%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.311-0.282-9%-0.252-19%-0.202-35%-0.202-35%
Free Cash Flow To Equity Per Share---0.215-0.249+16%0.106-303%0.043-597%0.043-597%
Gross Profit Margin--1.0001.0010%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---15.402--------
Intrinsic Value_10Y_min---13.129--------
Intrinsic Value_1Y_max---1.038--------
Intrinsic Value_1Y_min---1.019--------
Intrinsic Value_3Y_max---3.503--------
Intrinsic Value_3Y_min---3.336--------
Intrinsic Value_5Y_max---6.433--------
Intrinsic Value_5Y_min---5.938--------
Market Cap166838378.240-929%1716977484.8001919046297.280-11%1261816472.320+36%748438298.729+129%748438298.729+129%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.581-929%5.9815.519+8%2.586+131%1.907+214%1.907+214%
Pe Ratio-0.709+90%-7.298-7.954+9%-4.281-41%-2.879-61%-2.879-61%
Price Per Share1.030-929%10.60011.848-11%7.790+36%4.621+129%4.621+129%
Price To Free Cash Flow Ratio-0.829+90%-8.527-11.176+31%-6.340-26%-4.121-52%-4.121-52%
Price To Total Gains Ratio-4.954+90%-50.987-43.285-15%-30.545-40%-39.039-23%-39.039-23%
Quick Ratio--15.82720.325-22%20.324-22%16.870-6%16.870-6%
Return On Assets---0.186-0.164-12%-0.129-31%-0.131-29%-0.131-29%
Return On Equity---0.205-0.178-13%-0.108-47%-0.067-67%-0.067-67%
Total Gains Per Share---0.208-0.281+35%1.414-115%0.104-299%0.104-299%
Usd Book Value--287064000.000353401000.000-19%208498750.000+38%-15500235.294+105%-15500235.294+105%
Usd Book Value Change Per Share---0.208-0.281+35%1.414-115%0.104-299%0.104-299%
Usd Book Value Per Share--1.7722.182-19%1.287+38%-0.096+105%-0.096+105%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1994647484.8002252208797.280-11%2975818944.640-33%2493412179.733-20%2493412179.733-20%
Usd Eps---0.363-0.376+4%-0.364+0%-0.315-13%-0.315-13%
Usd Free Cash Flow---50340000.000-45734000.000-9%-40848750.000-19%-32693352.941-35%-32693352.941-35%
Usd Free Cash Flow Per Share---0.311-0.282-9%-0.252-19%-0.202-35%-0.202-35%
Usd Free Cash Flow To Equity Per Share---0.215-0.249+16%0.106-303%0.043-597%0.043-597%
Usd Market Cap166838378.240-929%1716977484.8001919046297.280-11%1261816472.320+36%748438298.729+129%748438298.729+129%
Usd Price Per Share1.030-929%10.60011.848-11%7.790+36%4.621+129%4.621+129%
Usd Profit---58819000.000-60946750.000+4%-58981250.000+0%-51054470.588-13%-51054470.588-13%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.208-0.281+35%1.414-115%0.104-299%0.104-299%
 EOD+3 -5MRQTTM+11 -22YOY+13 -195Y+10 -2310Y+10 -23

3.3 Fundamental Score

Let's check the fundamental score of Neumora Therapeutics, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.709
Price to Book Ratio (EOD)Between0-10.581
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than115.827
Current Ratio (MRQ)Greater than110.508
Debt to Asset Ratio (MRQ)Less than10.094
Debt to Equity Ratio (MRQ)Less than10.104
Return on Equity (MRQ)Greater than0.15-0.205
Return on Assets (MRQ)Greater than0.05-0.186
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Neumora Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.405
Ma 20Greater thanMa 501.275
Ma 50Greater thanMa 1001.621
Ma 100Greater thanMa 2005.428
OpenGreater thanClose1.090
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2025-03-30 20:34:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Neumora Therapeutics, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neumora Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--90.0%+90.0%
TTM--190.6%+190.6%
YOY--199.6%+199.6%
5Y--336.0%+336.0%
10Y--488.5%+488.5%
4.3.1.2. Return on Assets

Shows how efficient Neumora Therapeutics, Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • -18.6% Return on Assets means that Neumora Therapeutics, Inc. generated $-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neumora Therapeutics, Inc.:

  • The MRQ is -18.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.6%TTM-16.4%-2.2%
TTM-16.4%YOY-12.9%-3.5%
TTM-16.4%5Y-13.1%-3.3%
5Y-13.1%10Y-13.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.6%-11.8%-6.8%
TTM-16.4%-11.8%-4.6%
YOY-12.9%-11.7%-1.2%
5Y-13.1%-12.7%-0.4%
10Y-13.1%-14.2%+1.1%
4.3.1.3. Return on Equity

Shows how efficient Neumora Therapeutics, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • -20.5% Return on Equity means Neumora Therapeutics, Inc. generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neumora Therapeutics, Inc.:

  • The MRQ is -20.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.5%TTM-17.8%-2.7%
TTM-17.8%YOY-10.8%-7.0%
TTM-17.8%5Y-6.7%-11.1%
5Y-6.7%10Y-6.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.5%-15.5%-5.0%
TTM-17.8%-15.8%-2.0%
YOY-10.8%-14.7%+3.9%
5Y-6.7%-18.0%+11.3%
10Y-6.7%-19.2%+12.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Neumora Therapeutics, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Neumora Therapeutics, Inc. is operating .

  • Measures how much profit Neumora Therapeutics, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neumora Therapeutics, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--193.6%+193.6%
TTM--291.5%+291.5%
YOY--208.2%+208.2%
5Y--367.6%+367.6%
10Y--475.9%+475.9%
4.3.2.2. Operating Ratio

Measures how efficient Neumora Therapeutics, Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neumora Therapeutics, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.041-2.041
TTM-3.198-3.198
YOY-2.977-2.977
5Y-4.689-4.689
10Y-6.513-6.513
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Neumora Therapeutics, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Neumora Therapeutics, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.51 means the company has $10.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neumora Therapeutics, Inc.:

  • The MRQ is 10.508. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.177. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.508TTM14.177-3.669
TTM14.177YOY16.633-2.456
TTM14.1775Y14.753-0.576
5Y14.75310Y14.7530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.5083.616+6.892
TTM14.1773.873+10.304
YOY16.6334.496+12.137
5Y14.7535.932+8.821
10Y14.7536.223+8.530
4.4.3.2. Quick Ratio

Measures if Neumora Therapeutics, Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 15.83 means the company can pay off $15.83 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neumora Therapeutics, Inc.:

  • The MRQ is 15.827. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.325. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.827TTM20.325-4.498
TTM20.325YOY20.324+0.001
TTM20.3255Y16.870+3.455
5Y16.87010Y16.8700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.8272.939+12.888
TTM20.3253.326+16.999
YOY20.3244.252+16.072
5Y16.8705.921+10.949
10Y16.8706.474+10.396
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Neumora Therapeutics, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Neumora Therapeutics, Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neumora Therapeutics, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Neumora Therapeutics, Inc. assets are financed with 9.4% credit (debt) and the remaining percentage (100% - 9.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neumora Therapeutics, Inc.:

  • The MRQ is 0.094. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.075. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.094TTM0.075+0.020
TTM0.075YOY0.652-0.577
TTM0.0755Y1.114-1.039
5Y1.11410Y1.1140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0940.340-0.246
TTM0.0750.342-0.267
YOY0.6520.312+0.340
5Y1.1140.359+0.755
10Y1.1140.382+0.732
4.5.4.2. Debt to Equity Ratio

Measures if Neumora Therapeutics, Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.4% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neumora Therapeutics, Inc.:

  • The MRQ is 0.104. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.081. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.081+0.023
TTM0.081YOY0.048+0.033
TTM0.0815Y0.030+0.051
5Y0.03010Y0.0300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1040.393-0.289
TTM0.0810.428-0.347
YOY0.0480.395-0.347
5Y0.0300.451-0.421
10Y0.0300.493-0.463
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neumora Therapeutics, Inc. generates.

  • Above 15 is considered overpriced but always compare Neumora Therapeutics, Inc. to the Biotechnology industry mean.
  • A PE ratio of -7.30 means the investor is paying $-7.30 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neumora Therapeutics, Inc.:

  • The EOD is -0.709. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.298. Based on the earnings, the company is expensive. -2
  • The TTM is -7.954. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.709MRQ-7.298+6.589
MRQ-7.298TTM-7.954+0.657
TTM-7.954YOY-4.281-3.673
TTM-7.9545Y-2.879-5.075
5Y-2.87910Y-2.8790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.709-2.034+1.325
MRQ-7.298-2.510-4.788
TTM-7.954-3.189-4.765
YOY-4.281-3.248-1.033
5Y-2.879-6.225+3.346
10Y-2.879-6.955+4.076
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neumora Therapeutics, Inc.:

  • The EOD is -0.829. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.527. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.176. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.829MRQ-8.527+7.698
MRQ-8.527TTM-11.176+2.649
TTM-11.176YOY-6.340-4.835
TTM-11.1765Y-4.121-7.054
5Y-4.12110Y-4.1210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.829-2.789+1.960
MRQ-8.527-3.511-5.016
TTM-11.176-3.835-7.341
YOY-6.340-4.295-2.045
5Y-4.121-8.306+4.185
10Y-4.121-9.319+5.198
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Neumora Therapeutics, Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.98 means the investor is paying $5.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neumora Therapeutics, Inc.:

  • The EOD is 0.581. Based on the equity, the company is cheap. +2
  • The MRQ is 5.981. Based on the equity, the company is overpriced. -1
  • The TTM is 5.519. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD0.581MRQ5.981-5.400
MRQ5.981TTM5.519+0.462
TTM5.519YOY2.586+2.932
TTM5.5195Y1.907+3.612
5Y1.90710Y1.9070.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5811.838-1.257
MRQ5.9812.129+3.852
TTM5.5192.387+3.132
YOY2.5862.446+0.140
5Y1.9073.811-1.904
10Y1.9074.584-2.677
4.6.2. Total Gains per Share

2.4. Latest News of Neumora Therapeutics, Inc.

Does Neumora Therapeutics, Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Neumora Therapeutics, Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-03-30
14:47
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora TherapeuticsRead
2025-03-29
18:05
Class Action Lawsuit Reminder (NMRA): Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors - A Securities Fraud Class Action Lawsuit Has Been FiledRead
2025-03-28
23:02
NMRA IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRARead
2025-03-27
17:52
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NMRARead
2025-03-26
21:28
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRARead
2025-03-26
16:01
Neumora Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRARead
2025-03-26
04:04
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRARead
2025-03-25
22:40
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff MotionRead
2025-03-25
19:53
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - Contact Kessler Topaz Meltzer & Check, LLPRead
2025-03-24
18:46
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA)Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neumora Therapeutics, Inc..

4.8.3. Insider Transactions

Insiders are holding 27.524% of the shares of Neumora Therapeutics, Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-02-18Joshua PintoSELL80481.67
2025-02-18Michael Lee MilliganSELL19781.69
2024-10-18Matthew K FustSELL1404917.03
2024-10-09Robert A LenzSELL556315.01
2024-09-17Robert A LenzSELL3078811.81
2024-08-26Joshua PintoSELL3164211.78
2024-08-22Joshua PintoSELL2849611.63
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets316,972
Total Liabilities29,908
Total Stockholder Equity287,064
 As reported
Total Liabilities 29,908
Total Stockholder Equity+ 287,064
Total Assets = 316,972

Assets

Total Assets316,972
Total Current Assets314,055
Long-term Assets2,917
Total Current Assets
Cash And Cash Equivalents 142,148
Short-term Investments 165,430
Other Current Assets 6,477
Total Current Assets  (as reported)314,055
Total Current Assets  (calculated)314,055
+/-0
Long-term Assets
Property Plant Equipment 2,917
Long-term Assets  (as reported)2,917
Long-term Assets  (calculated)2,917
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities29,886
Long-term Liabilities22
Total Stockholder Equity287,064
Total Current Liabilities
Short-term Debt 1,853
Accounts payable 3,307
Other Current Liabilities 24,726
Total Current Liabilities  (as reported)29,886
Total Current Liabilities  (calculated)29,886
+/-0
Long-term Liabilities
Long-term Liabilities Other 22
Long-term Liabilities  (as reported)22
Long-term Liabilities  (calculated)22
+/-0
Total Stockholder Equity
Common Stock16
Retained Earnings -947,221
Accumulated Other Comprehensive Income 62
Other Stockholders Equity 1,234,207
Total Stockholder Equity (as reported)287,064
Total Stockholder Equity (calculated)287,064
+/-0
Other
Capital Stock16
Cash and Short Term Investments 307,578
Common Stock Shares Outstanding 160,984
Liabilities and Stockholders Equity 316,972
Net Debt -140,295
Net Invested Capital 287,064
Net Working Capital 284,169
Property Plant and Equipment Gross 4,966
Short Long Term Debt Total 1,853



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
197,946
0
0
451,975
429,297
382,837
363,582
0
426,234
392,093
359,952
544,749
496,195
450,211
404,473
352,537
316,972
316,972352,537404,473450,211496,195544,749359,952392,093426,2340363,582382,837429,297451,97500197,946
   > Total Current Assets 
193,841
0
0
443,081
415,603
362,923
340,390
387,955
387,955
359,959
336,611
525,735
478,279
442,785
398,319
348,608
314,055
314,055348,608398,319442,785478,279525,735336,611359,959387,955387,955340,390362,923415,603443,08100193,841
       Cash And Cash Equivalents 
191,977
0
0
439,145
409,247
291,179
174,402
0
240,943
210,870
204,218
412,284
374,038
182,927
150,678
275,714
142,148
142,148275,714150,678182,927374,038412,284204,218210,870240,9430174,402291,179409,247439,14500191,977
       Short-term Investments 
0
0
0
0
0
58,444
153,112
0
130,941
134,676
119,979
97,281
79,944
239,788
220,961
65,593
165,430
165,43065,593220,961239,78879,94497,281119,979134,676130,9410153,11258,44400000
       Net Receivables 
148
0
0
270
200
269
585
919
919
787
594
668
939
906
1,631
0
0
001,63190693966859478791991958526920027000148
       Other Current Assets 
0
0
0
0
0
12,981
0
13,534
15,102
13,626
11,820
16,170
23,358
19,164
25,049
7,301
6,477
6,4777,30125,04919,16423,35816,17011,82013,62615,10213,534012,98100000
   > Long-term Assets 
4,105
0
0
8,894
13,694
19,914
23,192
0
38,279
32,134
23,341
19,014
17,916
7,426
6,154
3,929
2,917
2,9173,9296,1547,42617,91619,01423,34132,13438,279023,19219,91413,6948,894004,105
       Property Plant Equipment 
3,922
0
0
4,504
4,041
3,804
9,698
10,642
10,642
9,707
8,683
7,888
6,858
5,911
4,941
3,929
2,917
2,9173,9294,9415,9116,8587,8888,6839,70710,64210,6429,6983,8044,0414,504003,922
       Long Term Investments 
0
0
0
0
0
0
9,369
0
23,511
0
9,892
9,913
9,845
302
0
0
0
0003029,8459,9139,892023,51109,369000000
       Long-term Assets Other 
183
0
0
4,390
9,653
2,303
4,125
0
4,126
2,928
4,766
1,213
1,213
1,213
0
0
0
0001,2131,2131,2134,7662,9284,12604,1252,3039,6534,39000183
> Total Liabilities 
292,330
0
0
752,422
754,518
748,854
758,290
0
873,084
26,326
873,493
32,056
27,119
25,669
23,214
31,798
29,908
29,90831,79823,21425,66927,11932,056873,49326,326873,0840758,290748,854754,518752,42200292,330
   > Total Current Liabilities 
9,370
0
0
20,951
23,278
17,927
22,862
23,697
23,697
21,778
26,088
29,123
25,111
24,609
23,125
31,743
29,886
29,88631,74323,12524,60925,11129,12326,08821,77823,69723,69722,86217,92723,27820,951009,370
       Short-term Debt 
764
0
0
1,229
1,056
1,042
2,591
0
3,370
3,346
3,323
3,398
6,756
6,982
7,214
2,745
1,853
1,8532,7457,2146,9826,7563,3983,3233,3463,37002,5911,0421,0561,22900764
       Accounts payable 
2,398
0
0
2,508
1,639
1,647
3,015
7,147
7,147
1,135
8,172
2,229
337
1,492
1,082
6,107
3,307
3,3076,1071,0821,4923372,2298,1721,1357,1477,1473,0151,6471,6392,508002,398
       Other Current Liabilities 
612
0
0
1,258
1,487
828
1,966
1,644
1,644
17,297
158
149
18,018
16,135
14,829
22,891
24,726
24,72622,89114,82916,13518,01814915817,2971,6441,6441,9668281,4871,25800612
   > Long-term Liabilities 
282,960
0
0
731,471
731,240
730,927
735,428
0
849,387
4,548
847,405
2,933
2,008
1,060
89
55
22
2255891,0602,0082,933847,4054,548849,3870735,428730,927731,240731,47100282,960
       Other Liabilities 
0
0
0
0
0
0
0
628
628
254
221
0
0
0
0
0
0
0000002212546286280000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
2,912
2,912
2,900
3,553
0
0
0
0
0
0
0000003,5532,9002,9122,9120000000
> Total Stockholder Equity
-94,384
0
0
-300,447
-325,221
-366,017
-394,708
0
-446,850
365,767
-513,541
512,693
469,076
424,542
381,259
320,739
287,064
287,064320,739381,259424,542469,076512,693-513,541365,767-446,8500-394,708-366,017-325,221-300,44700-94,384
   Common Stock
13
0
0
13
14
15
15
16
3
16
16
15
16
16
16
16
16
1616161616151616316151514130013
   Retained Earnings -947,221-888,402-815,855-757,155-703,434-594,704-541,677-503,134-467,509-467,509-410,019-379,647-336,605-309,63600-99,293
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
4,896
0
0
9,176
11,370
-716,065
16,166
-774
-822,257
25,496
-815,119
1,107,693
1,172,570
1,181,829
1,197,285
1,209,020
1,234,207
1,234,2071,209,0201,197,2851,181,8291,172,5701,107,693-815,11925,496-822,257-77416,166-716,06511,3709,176004,896



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-263,464
Operating Income-263,464-263,464
 
Operating Expense (+$)
Research Development200,927
Selling General Administrative62,537
Selling And Marketing Expenses0
Operating Expense263,464263,464
 
Net Interest Income (+$)
Interest Income19,933
Interest Expense-0
Other Finance Cost-0
Net Interest Income19,933
 
Pretax Income (+$)
Operating Income-263,464
Net Interest Income19,933
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-243,609-283,319
EBIT - interestExpense = 0
-243,609
-243,787
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-243,609
Earnings Before Interest and Taxes (EBITDA)-263,464
 
After tax Income (+$)
Income Before Tax-243,609
Tax Provision-178
Net Income From Continuing Ops-243,787-243,787
Net Income-243,787
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net19,855-19,933
 

Technical Analysis of Neumora Therapeutics, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neumora Therapeutics, Inc.. The general trend of Neumora Therapeutics, Inc. is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neumora Therapeutics, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Neumora Therapeutics, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neumora Therapeutics, Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.6 < 1.83 < 1.83.

The bearish price targets are: .

Know someone who trades $NMRA? Share this with them.👇

Neumora Therapeutics, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neumora Therapeutics, Inc.. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neumora Therapeutics, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neumora Therapeutics, Inc.. The current macd is -0.25193416.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neumora Therapeutics, Inc. price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neumora Therapeutics, Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neumora Therapeutics, Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neumora Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartNeumora Therapeutics, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neumora Therapeutics, Inc.. The current adx is 57.63.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Neumora Therapeutics, Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Neumora Therapeutics, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neumora Therapeutics, Inc.. The current sar is 1.182.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Neumora Therapeutics, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neumora Therapeutics, Inc.. The current rsi is 26.40. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Neumora Therapeutics, Inc. Daily Relative Strength Index (RSI) ChartNeumora Therapeutics, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neumora Therapeutics, Inc.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Neumora Therapeutics, Inc. price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Neumora Therapeutics, Inc. Daily Stochastic Oscillator ChartNeumora Therapeutics, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neumora Therapeutics, Inc.. The current cci is -113.89371783.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Neumora Therapeutics, Inc. Daily Commodity Channel Index (CCI) ChartNeumora Therapeutics, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neumora Therapeutics, Inc.. The current cmo is -47.59191344.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Neumora Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) ChartNeumora Therapeutics, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neumora Therapeutics, Inc.. The current willr is -97.82277379.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Neumora Therapeutics, Inc. Daily Williams %R ChartNeumora Therapeutics, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Neumora Therapeutics, Inc..

Neumora Therapeutics, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neumora Therapeutics, Inc.. The current atr is 0.12860847.

Neumora Therapeutics, Inc. Daily Average True Range (ATR) ChartNeumora Therapeutics, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neumora Therapeutics, Inc.. The current obv is -17,294,972.

Neumora Therapeutics, Inc. Daily On-Balance Volume (OBV) ChartNeumora Therapeutics, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neumora Therapeutics, Inc.. The current mfi is 20.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Neumora Therapeutics, Inc. Daily Money Flow Index (MFI) ChartNeumora Therapeutics, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neumora Therapeutics, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Neumora Therapeutics, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neumora Therapeutics, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.405
Ma 20Greater thanMa 501.275
Ma 50Greater thanMa 1001.621
Ma 100Greater thanMa 2005.428
OpenGreater thanClose1.090
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Neumora Therapeutics, Inc. with someone you think should read this too:
  • Are you bullish or bearish on Neumora Therapeutics, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neumora Therapeutics, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neumora Therapeutics, Inc.

I send you an email if I find something interesting about Neumora Therapeutics, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Neumora Therapeutics, Inc..

Receive notifications about Neumora Therapeutics, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.